Key result
Among Caucasian patients with stage I-II hypertension on amlodipine, the TT genotype of ABCB1 rs1045642 was associated with a higher rate of reaching target blood pressure than the CC genotype (43% vs 12%, P=0.02).
Why the study?
Does the ABCB1 rs1045642 polymorphism affect the efficacy and safety of amlodipine in Caucasian patients with stage I-II hypertension?
Cohort (n=100)
Does the ABCB1 rs1045642 polymorphism affect the efficacy and safety of amlodipine in Caucasian patients with stage I-II hypertension?
Absolute Event Rate: 43% vs 12%
p-value: p=0.02
The ABCB1 rs1045642 polymorphism significantly impacts the efficacy and safety of amlodipine in Caucasian patients with stage I-II hypertension, suggesting a potential role for pharmacogenetic testing.
Genotype may influence amlodipine BP response; hypothesis-generating and requires validation before guiding therapy.
Purpose: The aim of this study was to determine the impact of ABCB1 (MDR1) rs1045642 polymorphisms on the efficacy and safety of amlodipine in Caucasian patients. Patients and methods: The 12-week study included 100 patients. Patients with the newly diagnosed stage I–II hypertension (HT) were recruited to complete genotyping of the rs1045642 single-nucleotide polymorphism (SNP). The study design did not include a control group. Before treatment, all patients either did not undergo antihypertensive treatment at all or did not receive regular antihypertensive therapy. The initial dose was 5 mg/day. Four office blood pressure measurements, two 24-hour noninvasive ambulatory blood pressure measurements, and questionnaires of Tsvetov were used to evaluate the efficacy and safety of amlodipine. Results and conclusion: The highest antihypertensive effect in combination with the lowest incidence of adverse reactions was observed in the TT group, while patients with the CC genotype showed a low antihypertensive effect and the highest incidence of adverse effects. Patients with the CC genotype presented with adverse effects predominantly in the form of edema. A total of 33 patients reached the target blood pressure (SBP <140 mmHg; DBP <90 mmHg): two patients with the CC genotype (12%); 18 patients with the CT genotype (34%); and 13 patients with the TT genotype (43%). The intergroup differences were: CC vs CT, P =0.02; CC vs TT, P =0.02; and CT vs TT, P =0.05. The results of this study indicate the potential of pharmacogenetic testing for rs1045642 SNP when prescribing amlodipine for the first time in Caucasian patients with stage I–II arterial HT.
No takes yet. Share an insight, caveat, or question.
Сычев et al. (2018) conducted a cohort in Stage I-II hypertension (n=100). ABCB1 rs1045642 polymorphisms (TT and CT genotypes) vs. CC genotype was evaluated on Target blood pressure (SBP <140 mmHg; DBP <90 mmHg) (p=0.02). Among Caucasian patients with stage I-II hypertension on amlodipine, the TT genotype of ABCB1 rs1045642 was associated with a higher rate of reaching target blood pressure than the CC genotype (43% vs 12%, P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: